Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CTNM Stock Forecast 2026-2027
$14.53
Current Price
$543.22M
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to CTNM Price Targets
+92.7%
To High Target of $28.00
+51.4%
To Median Target of $22.00
-3.6%
To Low Target of $14.00
CTNM Price Momentum
+2.7%
1 Week Change
+12.9%
1 Month Change
+275.5%
1 Year Change
+27.1%
Year-to-Date Change
-11.0%
From 52W High of $16.33
+333.7%
From 52W Low of $3.35
📊 TOP ANALYST CALLS
Did CTNM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Contineum is one of their latest high-conviction picks.
Latest CTNM Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CTNM has a bullish consensus with a median price target of $22.00 (ranging from $14.00 to $28.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $14.53, the median forecast implies a 51.4% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jeffrey Hung at Morgan Stanley, suggesting a 3.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTNM Analyst Ratings
6
Buy
1
Hold
0
Sell
CTNM Price Target Range
Low
$14.00
Average
$22.00
High
$28.00
Current: $14.53
Latest CTNM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTNM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 6, 2026 | Baird | Joel Beatty | Outperform | Maintains | $20.00 |
| Jan 8, 2026 | Morgan Stanley | Jeffrey Hung | Equal-Weight | Downgrade | $14.00 |
| Nov 24, 2025 | Baird | Joel Beatty | Outperform | Maintains | $14.00 |
| Nov 21, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $22.00 |
| Sep 25, 2025 | Leerink Partners | Faisal Khurshid | Outperform | Initiates | $20.00 |
| Aug 18, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $21.00 |
| May 19, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $20.00 |
| May 15, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $31.00 |
| Mar 13, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $23.00 |
| Mar 7, 2025 | Baird | Joel Beatty | Outperform | Maintains | $16.00 |
| Mar 7, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Assumes | $25.00 |
| Jan 9, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $31.00 |
| Nov 7, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $31.00 |
| Oct 22, 2024 | Baird | Joel Beatty | Outperform | Initiates | $32.00 |
| Aug 14, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $32.00 |
| Apr 30, 2024 | RBC Capital | Brian Abrahams | Outperform | Initiates | $30.00 |
| Apr 30, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Initiates | $25.00 |
| Apr 30, 2024 | Stifel | Paul Matteis | Buy | Initiates | $29.00 |
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Competitors
The following stocks are similar to Contineum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial Data
Contineum Therapeutics, Inc. Class A Common Stock has a market capitalization of $543.22M with a P/E ratio of 26.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -26.9%.
Valuation Metrics
Market Cap
$543.22M
Enterprise Value
$303.85M
P/E Ratio
26.0x
PEG Ratio
-2.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+45.3%
Current Ratio
38.0x
Debt/Equity
2.8x
ROE
-26.9%
ROA
-18.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Business Model
About Contineum Therapeutics, Inc. Class A Common Stock
What They Do
Develops innovative therapeutic solutions in biotechnology.
Business Model
The company focuses on research and development of novel drug candidates addressing unmet medical needs. It generates revenue through the commercialization of these drugs, including potential partnerships and collaborations with other entities in the healthcare sector.
Additional Information
Continua Therapeutics targets diseases in oncology, neurology, and autoimmune disorders, positioning itself as a significant player in the biotech industry. Its commitment to pioneering next-generation pharmaceuticals could redefine treatment protocols and improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
51
CEO
Mr. Carmine N. Stengone MBA, MS
Country
United States
IPO Year
2024
Website
www.contineum-tx.comContineum Therapeutics, Inc. Class A Common Stock (CTNM) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
May 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Wall Street analysts project a 49.2% upside for Contineum Therapeutics, Inc. (CTNM), supported by positive earnings estimate revisions.
Why It Matters
Price targets suggesting a 49.2% upside for Contineum Therapeutics indicate strong growth potential, while positive earnings revisions may further boost investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Contineum Therapeutics (NASDAQ: CTNM) reported its Q1 2026 financial results and confirmed key clinical milestones, highlighting positive topline results from a chronic pain trial.
Why It Matters
Positive trial results indicate potential for successful product development, which can drive stock price and investor interest in Contineum Therapeutics.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Contineum Therapeutics granted inducement awards to two new non-executive employees under its 2026 Employment Inducement Equity Incentive Plan, as announced on October 23, 2023.
Why It Matters
Contineum Therapeutics is expanding its team, which may enhance its research capabilities and innovation in therapies, potentially impacting future growth and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Contineum Therapeutics (NASDAQ: CTNM) announced positive topline results from its Phase 1b trial of PIPE-791, a selective LPA1 receptor antagonist for chronic osteoarthritis treatment.
Why It Matters
Positive results from Contineum's Phase 1b trial for PIPE-791 could indicate a promising new treatment for chronic osteoarthritis, potentially boosting the company's stock value and market position.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Contineum Therapeutics granted a non-qualified stock option for 51,000 shares of Class A common stock on March 12, 2026, as an inducement award.
Why It Matters
The grant of stock options to Contineum's executives signals potential growth and alignment with shareholder interests, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
2 months ago
Quick Summary
Contineum Therapeutics (NASDAQ: CTNM) reported its Q4 2025 financial results and confirmed key clinical milestones, including the first patient dosed in a Phase 2 study for idiopathic pulmonary fibrosis.
Why It Matters
Contineum's strong Q4 results and initiation of a Phase 2 trial signal progress in its clinical pipeline, potentially boosting investor confidence and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CTNM Stock
What is Contineum Therapeutics, Inc. Class A Common Stock's (CTNM) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a median price target of $22.00. The highest price target is $28.00 and the lowest is $14.00.
Is CTNM stock a good investment in 2026?
According to current analyst ratings, CTNM has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $14.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CTNM stock?
Wall Street analysts predict CTNM stock could reach $22.00 in the next 12 months. This represents a 51.4% increase from the current price of $14.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Contineum Therapeutics, Inc. Class A Common Stock's business model?
The company focuses on research and development of novel drug candidates addressing unmet medical needs. It generates revenue through the commercialization of these drugs, including potential partnerships and collaborations with other entities in the healthcare sector.
What is the highest forecasted price for CTNM Contineum Therapeutics, Inc. Class A Common Stock?
The highest price target for CTNM is $28.00 from at , which represents a 92.7% increase from the current price of $14.53.
What is the lowest forecasted price for CTNM Contineum Therapeutics, Inc. Class A Common Stock?
The lowest price target for CTNM is $14.00 from Jeffrey Hung at Morgan Stanley, which represents a -3.6% decrease from the current price of $14.53.
What is the overall CTNM consensus from analysts for Contineum Therapeutics, Inc. Class A Common Stock?
The overall analyst consensus for CTNM is bullish. Out of 6 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $22.00.
How accurate are CTNM stock price projections?
Stock price projections, including those for Contineum Therapeutics, Inc. Class A Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 10, 2026 6:40 PM UTC